Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat
metastatic breast, ovarian, endometrial or cervical cancer not responding to standard
treatment.